About MELAGENIX
MELAGENIX is a Healthcare company based in Koln (Germany) founded in 2017 by Daniel Von Janowski, Georg Brunner, and Anton Strobe. Molecular diagnostic tests for skin cancer detection are developed. MELAGENIX has raised $8.92 million across 1 funding round from investors including BayBG Venture Capital and MIG Capital. Its focus areas include Life Sciences, Dermatology, In Vitro Diagnostics Tests and Skin Cancer. Its legal entity is NeraCare GmbH.
Company details
Founded in 2017 in Cologne, Germany, MELAGENIX operates in the biotechnology sector, focusing on molecular diagnostics for oncology. RT-PCR-based assays are developed to detect melanoma and assess AJCC staging in patients at clinical trial stages I-III. Tumor-specific information is provided to support treatment decisions, with operations centered on advancing diagnostic tools for skin cancer management.
- Headquarters Koln, Germany
- Founders Daniel Von Janowski, Georg Brunner, Anton Strobe
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website melagenix.info
- Legal Name Neracare Gmbh
- Total Equity Funding$8.92M (USD)
in 1 rounds
- Latest Funding Round$8.92M (USD), Series A
Mar 2020
- InvestorsBayBG Venture Capital
& 1 more
Funding Insights of MELAGENIX
MELAGENIX has successfully raised a total of $8.92M through 1 strategic funding round. The most recent funding activity was a Series A round of $8.92 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.92M
- Total Rounds 1
- Last Round Series A — $8.92M
- First Round $8.92M
(Mar 2020)
- Investors Count 2
All 1 funding rounds of MELAGENIX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2020 | $8.92M | Series A | – | BayBG Venture Capital |
2 investors in total: 2 institutional.
Investors in MELAGENIX
MELAGENIX has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include BayBG Venture Capital and MIG Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in series A to series B stages | baybg-vc.de | Munich, Germany | ||
VC Firm funding companies in Europe | mig.ag | Munich, Germany |
Investor details for MELAGENIX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MELAGENIX
3 people are tracked at MELAGENIX (3 in leadership).
| Name | Role | Group |
|---|---|---|
Daniel Von Janowski | Co-Founder & CPO | Leadership |
Georg Brunner | Co-Founder | Leadership |
Anton Strobe | Co-Founder | Leadership |
Complete people profiles for MELAGENIX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MELAGENIX
2 dated milestones of MELAGENIX across 3 years, from founding to its latest funding, stage changes and deals.
- Founded MELAGENIX is founded.
- Funding First funding round of $8.9M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Melagenix
Complete news archive for MELAGENIX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MELAGENIX
MELAGENIX was founded in 2017 and raised its 1st funding round 3 years after it was founded.
MELAGENIX is headquartered in Koln, Germany. It is registered at Koln, North Rhine-westphalia, Germany.
MELAGENIX is a funded company, having raised a total of $8.92M across 1 funding round to date. The company's 1st funding round was a Series A of $8.92M, raised on Mar 2020.
Founded in 2017 in Cologne, Germany, MELAGENIX operates in the biotechnology sector, focusing on molecular diagnostics for oncology. RT-PCR-based assays are developed to detect melanoma and assess AJCC staging in patients at clinical trial stages I-III. Tumor-specific information is provided to support treatment decisions, with operations centered on advancing diagnostic tools for skin cancer management.
MELAGENIX has 2 investors. Key investors include BayBG Venture Capital, and MIG Capital.
MELAGENIX operates through Neracare Gmbh.